ArticleAnales del sistema sanitario de Navarra2025
[Nirsevimab immunization effectiveness against respiratory syncytial virus hospitalization in newborns: two season of use in Navarre, Spain].
Article in Anales del sistema sanitario de Navarra, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention.Pediatric investigation · 2026Article
- [Anales del Sistema Sanitario de Navarra in 2025: Progress continues].Anales del sistema sanitario de Navarra · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is the leading cause of infant hospitalisation. In 2022, nirsevimab was approved in the European Union to prevent severe respiratory disease due to RSV during the first year of life. Our aim is to evaluate the effectiveness of nirsevimab immunoprophylaxis in new-borns for preventing RSV -related hospitalisations in Navarre, Spain, during its first two seasons of use.
methodsNirsevimab was offered free of charge to infants born from October to December 2023 and from September to December 2024. Each cohort was followed until February of the following year. Cases were infants hospitalised for PCR-confirmed RSV infection. Cox regression was used to estimate the hazard ratio of hospitalisation for immunised versus non-immunised children.
resultsNirsevimab was offered to 2,699 new-borns; of them, 2,541 (94.1%) received nirsevimab. In the 2023-2024 season, 17 RSV-related hospitalisations were recorded and 24 in the 2024-2025 season. The average risk of RSV hospitalisation was 7.6% in non-immunised new-borns versus 1.1% in immunised ones. Overall, effectiveness of nirsevimab was 79.5% (95% CI: 59.2 - 89.7), with estimates of 89.9% in 2023-2024 and 52.8% in 2024-2025, with no significant differences between seasons (p=0.055). On average, one RSV hospitalisation was prevented per 22.6 immunised infants.
conclusionsNirsevimab immunoprophylaxis substantially reduces RSV hospitalisations, helping ease paediatric hospital burden. However, as some immunised infants were still hospitalised, additional preventive measures remain necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.